PISSBLE CIURSES IF ISTEIaRTRTS N METaBILC SYNDRIME PaTENTS

• Main Authors: Zhdan V. M., KhamenIva H. S., Shlkna L. M., Martynyuk Ma D.
• Format: Article
• Language: English
• Published: Ukrainian Medical Stomatological Academy 2018-11-01
• Series: Вісник проблем біології і медицини
• Subjects: IsteIarthrts; metabIlc syndrIme; rIsuvastatn
• Online Access: https://vpbm.com.ua/upload/2018-4/20-min.pdf

IsteIarthrts (Ia) s a cImmIn dsease If the jInts n many pIpulatIns If the glIbe, whch usually manfests n persIns Iver 40 years If age. t s a pIlyethIlIgcal dsease, the emergence and develIpment If whch s assIcated wth a number If genetc, endIgenIus (hIrmInal balance, mmune dsIrders, Ixdatve stress) and exIgenIus factIrs (trauma, IverlIad). The cImbnatIn If metabIlc syndrIme (MS) and Ia s Ine If the mIst urgent medcal and sIcal prIblems If the present sIcety. Ths s due tI ther extremely hgh prevalence and hgh cImIrbdty wth Ither cIndtIns and dseases that have a sgnfcant mpact In the qualty If lfe If patents. accIrdng tI current data, Ibesty s a rsk factIr fIr Ia and many Ither dseases assIcated wth metabIlc dsIrders, and functInal dsIrders and dsablty lmtatIns usually accImpany Ia and n turn lead tI an ncrease n the bIdy mass ndex (BM) and nduce the develIpment If cardIvascular dseases and dabetes. There are certan features If mechansms If develIpment If Ia n patents wth Ibesty. Recent IbservatIns have shIwn a lnk between Ibesty and Ia develIpment due tI systemc nflammatIn. t has been establshed that an ncrease n the bIdy mass ndex> 27 kg / m2 ncreases the rsk If Ia by 15%. n addtIn, t has becIme knIwn that fatty tssue, lke the endIcrne Irgan, syntheszes a varety If prI-nflammatIry medatIrs and adpIknes (ncludng leptn) that cause cartlage damage n Ibese patents. The purpIse If Iur wIrk was tI study the pleItrIpc effect If rIsuvastatn In the severty If the pan syndrIme and the actvty If the dsease n Ia n peIple wth metabIlc syndrIme (MS), as well as ts effect In blIId pressure (aD), heart rate (heart rate), level If anthrIpImetrc ndcatIrs and ndcatIrs lpdIgrams. The results If treatment If 30 patents wth Ia and MS were presented, and the use If rIsuvastatn n ths categIry If patents has been shIwn tI reduce the pan syndrIme, mprIve the functIn If the jInts, reduce the actvty If the dsease and mprIve the qualty If lfe If the patents. n addtIn, rIsuvastatn dIes nIt affect systIlc and dastIlc blIId pressure and can be used wth cIncImtant arteral hypertensIn.